QuatRx Pharmaceuticals

QuatRx Pharmaceuticals is focused on discovering, licensing, developing and commercializing therapies for endocrine, metabolic and cardiovascular diseases.

With four major compounds in their research pipeline, QuatRx's two leading drug candidates --Ophena and fispemifene-- treat endocrine disorders associated with aging. Focused on post-menopausal symptoms in women and testosterone deficiencies in men, the company is aggressively moving forward with promising treatments that could reach markets with annual sales potentials in excess of $1 billion.

QuatRx has also partnered with Newton, PA-based Collagenex to develop and commercialize becocalcidiol, a skin cream used to treat psoriasis, a condition that more than 7.5 million Americans suffer from.

The company has also entered Phase 1 clinical studies on its new cholesterol-lowering compound, QRX-431.

There are 55 employees, with 25 based in Ann Arbor. Many recent additions have been employed at either Pfizer or Parke-Davis at one time or another.

Source: Julia Owens, QuatRx Pharmaceuticals Company

Company: QuatRx Pharmaceuticals

Website: Website

Address: 777 East Eisenhower Parkway, Suite 100
Ann Arbor, MI 48108

Phone: 734.913.9900

Healthcare, Life Sciences, Research

Growth Companies